Drugs Containing Excipient (Inactive Ingredient) ETHANOLAMINE

« Back to Dashboard

Ethanolamine Pharmaceutical Excipient Market Dynamics, Financial Trajectory, Regulation and IP Analysis

Last updated: October 4, 2026

Ethanolamine, also called monoethanolamine or MEA, is a commodity chemical with pharmaceutical applications as a pH adjuster, buffering agent, solubilizer and formulation intermediate. Its pharmaceutical market is small relative to its industrial, detergent, gas-treatment and agrochemical uses. The financial outlook is tied more to ethylene oxide, ammonia, energy and specialty-grade supply costs than to pharmaceutical exclusivity.

Ethanolamine has no drug-like patent moat, no Orange Book exclusivity and no biosimilar exposure. Commercial advantage comes from validated quality, regulatory documentation, supply continuity, low extractables and leachables risk, and the ability to produce consistent pharmaceutical-grade material.

What is ethanolamine and how is it used in pharmaceutical formulations?

Ethanolamine is a primary alkanolamine with the formula C2H7NO and CAS Registry Number 141-43-5. It contains both an amine and a hydroxyl group, allowing it to react with acids and function as a basic pH modifier.

Attribute	Data
Chemical name	2-Aminoethanol; monoethanolamine
Molecular formula	C2H7NO
Molecular weight	61.08 g/mol
CAS number	141-43-5
Physical form	Colorless to pale liquid
Primary industrial inputs	Ethylene oxide and ammonia
Main pharmaceutical functions	pH adjustment, buffering, solubilization, intermediate use
Pharmaceutical market position	Specialty niche within a large commodity market

Pharmaceutical applications can include liquid, topical, ophthalmic and other formulations where alkalinity, water miscibility or salt formation is required. The exact role depends on the formulation and route of administration. Ethanolamine should not be confused with ethanolamine oleate, a separate compound used in sclerotherapy products.

The principal commercial grades are technical, high-purity, cosmetic and pharmaceutical grades. Pharmaceutical material requires tighter control of impurities, water content, color, residual reaction products, trace metals and microbial quality than standard industrial material.

How large is the ethanolamine market and what is the pharmaceutical share?

Public market reports generally combine monoethanolamine with diethanolamine and triethanolamine. They also combine pharmaceutical demand with detergents, surfactants, gas treatment, cement additives, personal care, agrochemicals and industrial intermediates. As a result, a reliable standalone global revenue figure for pharmaceutical-grade ethanolamine is not publicly established.

The market structure is best understood in three layers:

Market layer	Demand profile	Financial characteristics
Total ethanolamines	MEA, DEA and TEA across industrial sectors	Large, cyclical, feedstock-sensitive
Monoethanolamine	Gas treatment, surfactants, detergents, agrochemicals and specialty uses	Higher volume, commodity pricing
Pharmaceutical-grade MEA	Formulation and regulated specialty supply	Low volume, higher qualification and documentation value

The pharmaceutical segment is likely a low-single-digit percentage of total ethanolamine demand, although public sources do not provide a consistent audited figure. Industrial applications set the production economics. Pharmaceutical demand influences grade premiums and supplier qualification, but it does not determine global capacity utilization.

What drives ethanolamine pricing?

The main cost variables are:

1. Ethylene oxide pricing and availability.
2. Ammonia pricing.
3. Natural gas and electricity costs.
4. Plant operating rates.
5. Freight, storage and hazardous-material handling.
6. Purification and pharmaceutical quality-control requirements.
7. Customer qualification and inventory requirements.

Ethanolamine is commonly produced by reacting ethylene oxide with ammonia. The process generates a distribution of monoethanolamine, diethanolamine and triethanolamine. Product separation and purification affect yield, energy consumption and cost. Producers with integrated ethylene oxide supply or efficient separation assets have a structural cost advantage.

What is the financial trajectory for pharmaceutical-grade ethanolamine?

The financial trajectory is stable to moderately growing rather than high-growth. Volume growth is constrained by the limited quantity of ethanolamine used directly in pharmaceutical formulations. Revenue expansion is more likely to come from grade upgrades, new formulation approvals, regional manufacturing changes and supply-chain premiums than from a rapid increase in drug demand.

Base-case trajectory

The base case has four characteristics:

• Low-to-mid single-digit volume growth in pharmaceutical applications.
• Periodic price volatility caused by feedstock and energy markets.
• Higher margins for qualified pharmaceutical supply than for technical-grade MEA.
• Continued concentration of production among integrated chemical companies.

Pharmaceutical-grade suppliers can obtain a premium because customers must qualify the material, maintain change-control records and demonstrate consistent impurity profiles. That premium does not create pricing power comparable with an active pharmaceutical ingredient. Customers can often qualify alternative suppliers if equivalence is demonstrated.

Upside factors

Demand could improve through:

• Growth in liquid and topical drug products.
• Increased use of ethanolamine in specialty delivery systems.
• Regional replacement of suppliers in Europe, North America or Asia.
• Demand for dual-source pharmaceutical excipients.
• Greater use of documented, high-purity excipients in regulated markets.

Downside factors

The main risks are:

• Substitution with sodium hydroxide, tromethamine, arginine or other pH-adjusting agents.
• Formulation redesign to avoid amine-related impurities.
• Industrial overcapacity depressing prices.
• Ethylene oxide outages.
• Increased scrutiny of residual impurities and nitrosamine formation pathways.
• Customer consolidation and direct procurement from large chemical producers.

Which companies manufacture ethanolamine and compete in pharmaceutical supply?

The competitive field includes large integrated chemical producers and regional specialty suppliers. Public disclosures generally report ethanolamines within broader chemical segments rather than as separate pharmaceutical businesses.

Company or supplier group	Competitive position
BASF	Integrated chemicals producer with alkanolamine production and global distribution
Dow	Large ethylene oxide and derivatives platform with relevant feedstock integration
INEOS Oxide	Major European and global producer of ethylene oxide derivatives
Nouryon	Specialty chemicals producer with amine and surfactant-related capabilities
SABIC and regional petrochemical producers	Feedstock and scale advantages in selected regions
Regional specialty distributors	Pharmaceutical documentation, repackaging and customer qualification

Supplier competition is based on manufacturing location, technical grade consistency, regulatory files, audit history, change notification, packaging and delivery reliability. The manufacturer of the active drug often does not manufacture the excipient.

What regulatory status applies to ethanolamine as a pharmaceutical excipient?

Ethanolamine is regulated as a chemical substance and excipient rather than as an independently approved drug. Regulatory status depends on the finished product, route of administration, concentration, specification and country.

The U.S. Food and Drug Administration evaluates inactive ingredients through the finished-product approval process. The FDA Inactive Ingredient Database is the principal public reference for prior use of excipients in approved drug products, including route and dosage-form information. Inclusion in the database does not constitute broad approval for every route or concentration (U.S. Food and Drug Administration, n.d.-a).

Pharmaceutical manufacturers typically assess:

• Identity and assay.
• Water content.
• Color and appearance.
• Residual ethylene oxide and related impurities.
• Diethanolamine and triethanolamine levels.
• Trace metals.
• Microbial quality where relevant.
• Nitrosamine risk.
• Elemental impurities.
• Container compatibility.
• Stability under formulation conditions.

The European Medicines Agency has published guidance requiring risk-based control of nitrosamine impurities in human medicinal products. Primary and secondary amines can be relevant to nitrosamine risk assessments when nitrosating conditions are present, although the actual risk depends on the formulation, process and impurity profile (European Medicines Agency, 2023).

Is ethanolamine listed in the USP-NF?

Ethanolamine may be supplied under a recognized pharmaceutical specification, but the applicable compendial status must be confirmed against the current United States Pharmacopeia-National Formulary and the product-specific monograph or customer specification. Suppliers commonly provide certificates of analysis against USP, Ph. Eur., ACS or internally validated pharmaceutical standards.

A buyer should distinguish between:

• Compendial compliance.
• FDA Inactive Ingredient Database precedent.
• GMP manufacturing.
• Drug-master-file support.
• Finished-product regulatory acceptance.

These are separate regulatory attributes.

What patents protect ethanolamine?

No active composition-of-matter patent protects ethanolamine itself. The compound is an established chemical with industrial production history extending over many decades. A company cannot obtain a meaningful new-product monopoly over ordinary ethanolamine as a chemical entity.

Potentially relevant IP categories are narrower:

IP category	Current commercial relevance
Composition-of-matter patents	No meaningful protection for ordinary ethanolamine
Manufacturing-process patents	Possible protection for catalysts, separations, purification and energy efficiency
Formulation patents	Possible protection when ethanolamine is used in a specific drug composition
Use patents	Possible for a narrow therapeutic or technical use
Packaging and stability know-how	Often protected as confidential know-how rather than patents
Analytical methods	Usually weak as a standalone barrier

Patent risk is therefore product-specific. A pharmaceutical company using ethanolamine may face patent issues relating to its finished dosage form, active ingredient or method of treatment, but not because ethanolamine itself is patented.

What is the Orange Book status of ethanolamine?

Ethanolamine has no standalone Orange Book listing because the Orange Book lists approved drug products, not general-purpose excipients. It has no independent New Chemical Entity exclusivity, five-year exclusivity, three-year clinical investigation exclusivity or 180-day generic exclusivity.

If ethanolamine is used in an approved drug, the relevant Orange Book patents would generally cover the active ingredient, drug product, formulation or method of use. The excipient itself would not ordinarily generate an Orange Book patent listing.

Are there Paragraph IV challenges or generic entry risks?

There are no meaningful Paragraph IV challenges directed at ethanolamine as an excipient. Paragraph IV litigation applies to patents listed against an approved reference drug, not to commodity excipients sold independently.

Generic entry risk exists at the finished-product level. The presence of ethanolamine may affect a generic applicant’s formulation design, but it does not independently block approval. A generic manufacturer can use ethanolamine, substitute another excipient or develop a non-infringing formulation, subject to equivalence, stability and regulatory requirements.

The principal commercial risk for an ethanolamine supplier is customer substitution, not patent invalidation.

What formulation patents and manufacturing barriers matter?

Formulation patents may protect:

• A specific concentration range.
• A pH-adjustment system combining ethanolamine with another buffer.
• A stable drug-excipient combination.
• A topical or ophthalmic delivery system.
• A low-impurity formulation.
• A controlled-release or solubilized dosage form.

Manufacturing barriers are more practical than legal. They include qualified production assets, high-purity distillation, impurity control, validated analytical methods, GMP documentation and a proven change-control system.

A pharmaceutical customer may resist switching suppliers because even a chemically equivalent material can require extractables testing, stability work, process validation and regulatory filing updates. This creates a qualification barrier, but not an absolute exclusivity right.

What licensing deals and settlement agreements affect ethanolamine?

No major publicly disclosed licensing transaction or patent settlement is known to create market exclusivity for pharmaceutical-grade ethanolamine. Supply contracts are generally private and may include volume commitments, geographic allocation, price formulas, dual-sourcing provisions and change-notification obligations.

The absence of public settlements is consistent with the product’s commodity-excipient profile. Commercial negotiations focus on supply security and quality documentation rather than patent rights.

How does ethanolamine compare with competing pharmaceutical pH adjusters?

Excipient	Main advantage	Main limitation
Ethanolamine	Water miscibility, alkalinity, salt formation and liquid handling	Amine-related impurity and nitrosamine assessment
Tromethamine	Established buffer capacity and pharmaceutical use	Higher cost and formulation-specific compatibility
Sodium hydroxide	Low cost and strong pH adjustment	Limited buffering and caustic handling
Potassium hydroxide	Strong alkalinity	Salt and compatibility considerations
Arginine	Buffering and amino-acid profile	Higher cost and possible formulation interactions
Citrate or phosphate systems	Broad pharmaceutical familiarity	Buffer capacity and ionic compatibility limits

Ethanolamine is most competitive where the formulation needs a soluble organic base, salt-forming capability or a specific pH profile. It is less attractive where the sponsor wants to minimize amine-related impurity assessments.

What geographic and supply-chain risks affect ethanolamine?

Supply is geographically diversified but remains exposed to regional ethylene oxide outages, chemical-plant maintenance and transport restrictions. Europe faces relatively high energy and regulatory costs. North America benefits from integrated petrochemical infrastructure. Asia has significant chemical manufacturing capacity and is important for both supply and pharmaceutical demand.

Pharmaceutical customers typically mitigate risk through:

• Approved secondary suppliers.
• Regional inventory.
• Multiple manufacturing sites.
• Tight raw-material specifications.
• Supplier audits.
• Formal change-control agreements.
• Retention samples and stability monitoring.

The most significant barrier is not a patent right. It is the cost and time required to qualify a replacement source without affecting a registered drug product.

Key Takeaways

• Ethanolamine is a mature commodity chemical with a small pharmaceutical-grade niche.
• Pharmaceutical demand is less important to global volume than detergents, gas treatment, surfactants and industrial applications.
• Financial performance is driven by ethylene oxide, ammonia, energy, plant utilization and purification costs.
• Pharmaceutical-grade material earns a quality and qualification premium but does not have drug-like pricing power.
• Ethanolamine has no standalone Orange Book exclusivity and is not subject to Paragraph IV challenges as an excipient.
• Composition-of-matter patent protection is not commercially relevant.
• Process patents, quality systems, supplier qualification and impurity control create the main practical barriers.
• Nitrosamine risk assessment is a central regulatory issue for amine-containing excipients.
• Generic entry risk applies to finished drug products using ethanolamine, not to ethanolamine itself.
• The base-case financial outlook is stable, with moderate pharmaceutical growth and continued commodity-price volatility.

FAQs

Is ethanolamine the same as ethanolamine oleate?

No. Ethanolamine is monoethanolamine, a small alkanolamine. Ethanolamine oleate is an ester-related product used in specific medical applications, including sclerotherapy. Their regulatory profiles and formulation uses differ.

Can ethanolamine be replaced by tromethamine?

Potentially, but substitution requires formulation development, compatibility testing, stability studies and regulatory assessment. The two materials have different buffering behavior, molecular weights and impurity profiles.

Does ethanolamine require a drug master file?

A drug master file may be useful when a supplier wants to provide confidential manufacturing information to drug-product sponsors. It is not automatically required for every excipient supplier or every finished-product application.

Is pharmaceutical-grade ethanolamine more profitable than technical-grade material?

It can generate a higher unit margin because of tighter specifications, documentation and customer qualification. Its total profitability remains constrained by lower volumes and competition from integrated chemical producers.

Can a generic drug use a different pH adjuster instead of ethanolamine?

Yes, if the alternative produces an equivalent and acceptable finished product. The generic applicant must satisfy formulation, quality, stability, bioequivalence and regulatory requirements and avoid applicable finished-product patent claims.

References

1. European Medicines Agency. (2023). Nitrosamine impurities in human medicinal products: Questions and answers. https://www.ema.europa.eu/

2. European Chemicals Agency. (n.d.). Ethanolamine: Substance information. https://echa.europa.eu/

3. International Council for Harmonisation. (2022). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org/

4. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (n.d.-b). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

7. OECD. (2004). SIDS initial assessment report for ethanolamine. Organisation for Economic Co-operation and Development. https://www.oecd.org/chemicalsafety/-